Applying health economics for policy decision making: Do devices differ from drugs?

Europace

Volumn 13, Issue SUPPL. 2, 2011, Pages

  Sorenson, Corinna ^a,e   Tarricone, Rosanna ^b,e   Siebert, Markus ^c,e   Drummond, Michael ^a,c,d,e  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b BOCCONI UNIVERSITY   (Italy)

^c St Jude Medical   (Belgium)

^d UNIVERSITY OF YORK   (United Kingdom)

^e European Health Technology Institute for Socio Economic Research (EHTI)   (Belgium)

Author keywords

Cardiac implantable electrical devices; Economic evaluation; Health technology assessment; Implantable cardioverter defibrillator; Medical devices

Indexed keywords

ARTICLE; CARDIOVASCULAR EQUIPMENT; CLINICAL RESEARCH; DECISION MAKING; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH PROGRAM; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; COST-BENEFIT ANALYSIS; DECISION MAKING; ELECTRIC STIMULATION THERAPY; EUROPE; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH POLICY; HOSPITALIZATION; PREVALENCE;

EID: 79955637666     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur089     Document Type: Article

References (34)

1. Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements for new drugs: the fourth hurdle. BMJ 2004;329:972-5. (Pubitemid 39422918)
2. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE; 2008.
3. Drummond MF, Schwartz JS, Jonsson B, Luce BR, Neumann PJ, Siebert U et al.. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008;23:244-58. (Pubitemid 351950160)
4. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: Oxford Medical Publications; 2005.
5. Gold M, Siegel J, Russell LB, Weinstein M. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
6. Tarn TY, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004;10:5-12.
7. Drummond MF, Griffin A, Tarricone R. Economic evaluation for devices and drugs. Same or different? Value Health 2009;12:402-4.
8. Centre for Review and Dissemination. Abstractors Guide for NHSEED. York: CRD; 2009.
9. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter defibrillators. N Engl J Med 2005;353:1471-80.
10. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS et al.. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001;135:870-83. (Pubitemid 33070683)
11. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R et al.. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Circulation 1998;97:2129-35. (Pubitemid 28262120)
12. Bank AJ, Mir SH, Nguyen DQ, Bolman RM 3rd, Shumway SJ, Miller LW et al.. Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. Ann Thorac Surg 2000;69:1369-75. (Pubitemid 30434860)
13. Rinfret S, Cohen DJ, Lamas GA, Fleischmann KE, Weinstein MC, Orav J et al.. Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction. Circulation 2005;111:165-72. (Pubitemid 40139727)
14. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH et al.. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary ste- noses: results from the sirolimus-eluting balloon expandable stent in the treat-ment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation 2004;100:508-14. (Pubitemid 39031165)
15. Bagust A, Grayson AD, Palmer ND, Perry RA, Walley T et al.. Cost-effectiveness of drug eluting coronary artery stenting in the UK setting: cost-utility study. Heart 2006;92:68-74. (Pubitemid 43021858)
16. Zwanzinger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM et al.. The cost-effectiveness of implantable cardioverter defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2006; 47:2310-8. (Pubitemid 43795065)
17. Cowie MR, Marshall D, Drummond M, Ferko N, Maschio M, Ekman M et al.. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace 2009;11:716-26.
18. National Institute for Health and Clinical Excellence. Dual-chamber Pacemakers for Symptomatic Bradycardia Due to Sick Sinus Syndrome and/or Atrioventricular Block. London: NICE; 2005.
19. National Institute for Health and Clinical Excellence. Cardiac Resynchronisation Therapy for the Treatment of Heart Failure. London: NICE; 2007.
20. Belgium Health Care Knowledge Centre. Percutaneous heart valve implantation in congenital and degenerative value disease. A rapid health technology assessment. KCE Reports 95C. Brussels: KCE; 2008.
21. Venditti FJ, O'Connell M, Martin DT, Shahian DM. Transvenous cardioverter defibrillators: cost implications of a less invasive approach. Pacing Clin Electrophysiol 1995;18(Part I):711-5.
22. Weintraub WS, Mahoney EM, Zhang Z, Chu H, Hutton J, Buxton M et al.. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart 2004;90:782-8. (Pubitemid 38813640)
23. Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW et al.. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial. Circulation 2001;104:3039-45. (Pubitemid 34014054)
24. Reynolds MR, Neild N, Ho KKL, Berezin R, Cosgrove RS, Lager RA et al.. Clinical and economic outcomes of mutivessel coronary stenting compared with bypass surgery: a single-center US experience. Am Heart J 2003;145:334-42. (Pubitemid 36207957)
25. Peterson ED, Cowper PA, DeLong ER, Zidar JP, Stack RS, Mark DB et al.. Acute and long-term cost implications of coronary stenting. J Am Coll Cardiol 1999;33: 1610-8.
26. Calvert MJ, Freemantle N, Yao G, Cleland JG, Billingham L, Daubert JC et al.. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 2005;26:2681-8. (Pubitemid 41746691)
27. Nichol G, Kaul P, Huszti E, Bridges JF. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004;141: 343-51.
28. Larsen G, Hallstrom A, McAnulty J, Pinski S, Olarte A, Sullivan S et al.. Costeffectiveness of the implantable cardioverter defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias. Circulation 2002;105: 2049-57.
29. Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM et al.. HRS/EHRA expert consensus on the monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of techniques, indications, personnel, frequency and ethical considerations. Europace 2008;10:707-25.
30. Le Goff-Pronost M, Sicotte C. The added value of thorough economic evaluation of telemedicine networks. Eur J Health Econ 2010;11:45-55.
31. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C et al.. Randomized comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998;352:673-81. (Pubitemid 28398701)
32. Brophy JM, Erickson LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care 2005;21:326-33. (Pubitemid 41099213)
33. Mittman N, Brown A, Seung SJ, Coyle D, Cohen E, Brophy J et al.. Economic evaluation of drug eluting stents. Technology Report No. 53. Canadian Coordinating Office for Health Technology Assessment; February 2005. Available at: https://www.ccohta.ca/publications/pdf/272-drug-eluting-stents-tr-e.pdf.
34. National Institute for Health and Clinical Excellence. Coronary Artery Disease: Coronary Stents (TA152). London: NICE; 2008.